03 Oct

BLOOD 2021

News

Congratulations to all investigators who contributed and presented the following accepted presentation and abstracts at BLOOD 2021.

  • Clinical characteristics of Australian treatment-naïve classical Hodgkin Lymphoma (cHL) patients from the Lymphoma and Related Diseases Registry (LaRDR)
  • Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian cohort: an analysis of the Lymphoma and Related Diseases Registry
  • Ibrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL): interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry
  • Ibrutinib in relapsed/refractory chronic lymphocytic leukaemia: interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry
  • Patterns of treatment and outcomes in patients with large B-cell lymphoma: The Australian real-world experience
  • Real world management of Lymphoma and Related diseases in Australia: The first five years of the Lymphoma and Related Diseases Registry (LaRDR)

Thank you for supporting our colleagues virtually at BLOOD. See you again next year!

4500th Patient Enrolm… August 3, 2021 Women In Lymphoma Web… October 4, 2021